GLPwatch
Papers (12034)
Page 159 of 201, ranked by citation count.
- Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.
- Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.
- Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.
- GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.
- Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.
- Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
- Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice.
- Letter to Liu et al.'s "Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome".
- Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.
- Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
- An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.
- [Effect of exendin-4 on monocyte chemoattractant protein-1 expression in cultured rat glomerular mesangial cells induced by tumor necrosis factor-α in vitro].
- Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists.
- Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
- Semaglutide in weight management - Author's reply.
- Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.
- Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.
- Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
- New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
- Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot.
- [Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.
- Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.
- Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide.
- Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.
- New Drug for Type 2 Diabetes.
- Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.
- Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Is global interest in fasting, intermittent fasting and the liver shifting?
- Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
- WEIGHT LOSS IN A YOUNG PATIENT WITH TYPE 2 DIABETES: CHALLENGES OF DIABETES MANAGEMENT USING ONLINE PROGRAM OF GOOD NUTRITION (CASE REPORT).
- High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.
- [Therapy of obesity with liraglutide. NN8022-1807 study].
- Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity-Reply.
- Exosomal miR-450b-5p Secreted from Exendin-4-Stimulated Endothelial Cells Protects Retinal Ganglion Cells Against Ischemia Reperfusion Injury.
- [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
- [The glucagon-like peptide-1 receptor-agonist semaglutide].
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.
- Holistic View of Tirzepatide's Role in Obesity-Related HFpEF.
- A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
- Dulaglutide slows kidney disease in type 2 diabetes.
- Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.
- Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.
- Injectable drugs for weight management.
- Liraglutide: can it make a difference in the treatment of type 2 diabetes?
- Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.
- Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
- Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.
- Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.
- Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database.
- Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.